SSSumita Madhok Strander

Sumita Madhok Strander

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sumita Madhok Strander has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    “Am I ever going to find myself again?”: Identity destabilization in patients with isocitrate dehydrogenase-mutant gliomas

    by Daniel Chiu, Kelcie D Willis, Jessica D Whitman, Sumita M Strander, Vanessa L Merker, Jennifer S Temel, Lara Traeger, Deborah A Forst

    Background: Patients with isocitrate dehydrogenase (IDH)-mutant gliomas often experience prolonged survival but frequently have persistent psychological distress and impaired quality of life (QOL). While prior research has characterized symptomatology and functional outcomes, less is known about how factors such as age and developmental stage shape distress and coping in this population. Our study sought to better understand these psychosocial dimensions of living with an IDH-mutant glioma, to inform the design of tailored supportive care. Methods: We conducted semistructured interviews with adults aged 18-65 years diagnosed with IDH-mutant gliomas (n = 20) receiving care at a large academic medical center. We used stratified purposeful sampling to ensure variation in age. Our multidisciplinary team coded and analyzed interview transcripts using reflexive thematic analysis. Results: Participants’ experiences coalesced around a central concept of destabilized identity, reflected in 5 interrelated themes: (1) yearning for an idealized past self; (2) shifting social roles; (3) existential uncertainty; (4) informational uncertainty; and (5) diverse emotional responses to identity conflict. Participants reported a loss of continuity with their premorbid selves, uncertainty about the future, and worries about sustaining cognitive and social functioning. This identity disruption was particularly distressing for younger adults navigating careers, relationships, and long-term life planning. Many expressed unmet support needs despite ongoing oncologic care. Conclusions: Disruption of personal identity emerged as a central feature of the experience of living with an IDH-mutant glioma. Supportive care that acknowledges and helps patients adapt to changes in their sense of self may improve overall psychosocial well-being and QOL.

  • Improved coping and self-efficacy drive improvements in mood among caregivers of patients with primary malignant brain tumors: Results from a randomized controlled trial

    by Kelcie D Willis, Deborah A Forst, Nora Horick, Sumita M Strander, Jessica Whitman, Amy Corveleyn, Timothy Sannes, Jennifer S Temel, Joseph A Greer, Areej El-Jawahri, et al.

    Background: In a recent randomized controlled trial, caregivers of patients diagnosed with primary malignant brain tumors (PMBT) who received NeuroCARE—a 6-session, cognitive-behavioral, telehealth intervention—demonstrated improved anxiety and depression symptoms at 11 weeks post-randomization compared to caregivers assigned to usual care (UC). We explored whether these intervention effects were mediated by improvements in coping and self-efficacy. Methods: We examined data from caregivers of patients with PMBT randomized to receive either NeuroCARE or UC (N = 120). Participants completed assessments of anxiety and depression symptoms (Hospital Anxiety and Depression Scale), coping (Measure of Current Status), and self-efficacy (Lewis Cancer Self-Efficacy Scale) at baseline, 11 weeks, and 16 weeks. We conducted 4 simple mediation regression models using the Preacher & Hayes bootstrapping method to examine whether improvements in coping or self-efficacy from baseline to 11 weeks mediated intervention effects on 11-week anxiety or depression symptoms. Results: The sample (N = 120; Mage = 53 years) predominantly consisted of participants who self-identified as female (82.5%), White (91.7%), and spouses/partners (70.0%) caring for a patient with glioblastoma (84%). Improvements in 11-week anxiety symptoms in caregivers assigned to NeuroCARE were mediated by improved coping (indirect effect = −1.44, SE = 0.49, 95% CI [−2.50, −0.54]) and self-efficacy (indirect effect=−1.29, SE = 0.42, 95% CI [−2.16, −0.52]). Similarly, improvements in 11-week depression symptoms were mediated by improved coping (indirect effect=-1.43, SE = 0.38, 95% CI [−2.21, −0.74]) and self-efficacy (indirect effect = −0.95, SE = 0.32, 95% CI [−1.60, −0.36]). Conclusion: The NeuroCARE intervention improves mood by enhancing coping skills and improving caregivers’ self-efficacy in caregivers of patients with PMBT.

  • NeuroCARE: A Randomized Controlled Trial of a Psychological Intervention for Caregivers of Patients With Primary Malignant Brain Tumors

    by Deborah A. Forst, Alyx F. Podgurski, Sumita M. Strander, Jessica D. Whitman, Shibani Datta, Kedie Pintro, Nora K. Horick, Kelcie D. Willis, Timothy S. Sannes, Joseph A. Greer, et al.

    PURPOSE: Caregivers of patients with primary malignant brain tumors (PMBT) experience significant psychological distress. We assessed the effect of a psychological intervention (NeuroCARE) on anxiety symptoms among PMBT caregivers. METHODS: We conducted a randomized trial of NeuroCARE versus usual care in PMBT caregivers with elevated anxiety (Generalized Anxiety Disorder-7 score ≥5) within 6 months of the patient's diagnosis. NeuroCARE was developed for PMBT caregivers and consists of six telehealth sessions with a behavioral health specialist. Participants completed surveys at baseline, 11-week (postintervention), and 16-week (1-month postintervention) time points. The primary outcome was 11-week anxiety symptoms (Hospital Anxiety and Depression Scale [HADS]-Anxiety Subscale). We also measured depression symptoms (HADS-Depression Subscale), quality of life (QOL; Caregiver QOL survey), caregiver burden (Caregiver Reaction Assessment), self-efficacy (Lewis Cancer Self-Efficacy Scale), coping (Measure of Current Status), and post-traumatic stress disorder (PTSD) symptoms (PTSD Checklist for DSM-5). We conducted analysis of covariance and linear mixed-effects regression analyses to examine intervention effects on study outcomes. RESULTS: We enrolled 120 caregivers (60/group) between October 2019 and June 2022; 105 were evaluable for the primary outcome. At 11 weeks, NeuroCARE participants reported significantly lower anxiety symptoms than usual care participants ( M , 8.87 v 10.69; P = .008). NeuroCARE caregivers also reported significantly lower depression symptoms ( M , 6.08 v 7.77; P = .004), and better self-efficacy ( M , 128.81 v 111.17; P < .001) and coping ( M , 32.25 v 25.65; P < .001) at 11 weeks. Study groups did not differ significantly in 11-week QOL, caregiver burden, or PTSD symptoms. In longitudinal analyses, intervention effects on depression symptoms, self-efficacy, and coping were sustained. CONCLUSION: A novel, population-specific psychological intervention led to improved anxiety and depression symptoms, self-efficacy, and coping among PMBT caregivers.


  • Open Access

    Study protocol for NeuroCARE: a randomised controlled trial of a psychological intervention for caregivers of patients with primary malignant brain tumours

    by Deborah Anne Forst, John Y Rhee, Michelle Marie Mesa, Alyx F Podgurski, Sumita Madhok Strander, Shibani Datta, Emilia Kaslow-Zieve, Nora K Horick, Joseph A Greer, Areej El-Jawahri, et al.

    Introduction Caregivers of patients with primary malignant brain tumours experience substantial psychological distress while caring for someone with a progressive, life-limiting neurological illness. However, there are few interventions aimed at addressing the psychosocial needs of this population. We developed and are testing a population-specific, evidence-based, telehealth intervention (NeuroCARE) to reduce anxiety symptoms and improve psychosocial functioning in this caregiver population. Methods and analysis This study is a non-blinded, randomised controlled trial of a psychological intervention for caregivers of patients with primary malignant brain tumours receiving care at the Massachusetts General Hospital Cancer Center or Dana-Farber Cancer Institute. We will enrol 120 caregivers who screen positive for heightened anxiety. Participants will be randomised 1:1 to the NeuroCARE intervention or a usual care control condition. Caregivers assigned to NeuroCARE will complete six individual telehealth sessions with a trained behavioural health specialist over 12 weeks. Caregivers randomised to the control condition will receive usual care, including possible referral to social work or other appropriate resources. Participants will complete self-report questionnaires at baseline and 11 weeks and 16 weeks postrandomisation. The primary outcome is anxiety symptoms at 11 weeks among NeuroCARE participants, compared with usual care. Secondary outcomes include caregiver-reported depressive symptoms, quality of life, caregiver burden, caregiving self-efficacy, perceived coping skills and post-traumatic stress disorder symptoms. We also will explore potential mediators of the NeuroCARE effect on caregiver anxiety symptoms. Ethics and dissemination The study is funded by a Career Development Award from Conquer Cancer, the American Society of Clinical Oncology Foundation (award number 2019CDA-7743456038) and approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board (Protocol #19-250 V.10.1). The study will be reported in accordance with the Consolidated Standards of Reporting Trials statement for non-pharmacological trials. Results will be presented at scientific meetings and in peer-reviewed journals. Trial registration number NCT04109209


  • Blood Pressure Trajectory Groups and Outcome After Endovascular Thrombectomy: A Multicenter Study

    by Nils H. Petersen, Sreeja Kodali, Can Meng, Fangyong Li, Cindy Khanh Nguyen, Krithika U. Peshwe, Sumita Strander, Andrew Silverman, Alexandra Kimmel, Anson Wang, et al.

    Background: Elevated blood pressure after endovascular thrombectomy (EVT) has been associated with an increased risk of hemorrhagic transformation and poor functional outcomes. However, the optimal hemodynamic management after EVT remains unknown, and the blood pressure course in the acute phase of ischemic stroke has not been well characterized. This study aimed to identify patient subgroups with distinct blood pressure trajectories after EVT and study their association with radiographic and functional outcomes. Methods: This multicenter retrospective cohort study included consecutive patients with anterior circulation large-vessel occlusion ischemic stroke who underwent EVT. Repeated time-stamped blood pressure data were recorded for the first 72 hours after thrombectomy. Latent variable mixture modeling was used to separate subjects into five groups with distinct postprocedural systolic blood pressure (SBP) trajectories. The primary outcome was functional status, measured on the modified Rankin Scale 90 days after stroke. Secondary outcomes included hemorrhagic transformation, symptomatic intracranial hemorrhage, and death. Results: Two thousand two hundred sixty-eight patients (mean age [±SD] 69±15, mean National Institutes of Health Stroke Scale 15±7) were included in the analysis. Five distinct SBP trajectories were observed: low (18%), moderate (37%), moderate-to-high (20%), high-to-moderate (18%), and high (6%). SBP trajectory group was independently associated with functional outcome at 90 days ( P P =0.0003 and adjusted odds ratio, 2.2 [95% CI, 1.5–3.2], P P =0.04). No significant association was found between trajectory group and hemorrhagic transformation. Conclusions: Patients with acute ischemic stroke demonstrate distinct SBP trajectories during the first 72 hours after EVT that have differing associations with functional outcome. These findings may help identify potential candidates for future blood pressure modulation trials.